Cns Pharmaceuticals Stock Fundamentals
| CNSP Stock | USD 0.12 0.01 7.69% |
Cns Pharmaceuticals fundamentals help investors to digest information that contributes to Cns Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Cns Stock. The fundamental analysis module provides a way to measure Cns Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cns Pharmaceuticals stock.
At this time, Cns Pharmaceuticals' Interest Expense is relatively stable compared to the past year. As of 11/28/2024, Research Development is likely to grow to about 14.8 M, though Operating Income is likely to grow to (17.9 M). Cns | Select Account or Indicator |
Cns Pharmaceuticals Company Shares Outstanding Analysis
Cns Pharmaceuticals' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Cns Pharmaceuticals Shares Outstanding | 40.75 M |
Most of Cns Pharmaceuticals' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cns Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cns Shares Outstanding Historical Pattern
Today, most investors in Cns Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cns Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Cns Pharmaceuticals shares outstanding as a starting point in their analysis.
Cns Pharmaceuticals Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Cns Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Cns Pharmaceuticals has 40.75 M of shares currently outstending. This is 77.43% lower than that of the Pharmaceuticals sector and 61.87% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 92.87% higher than that of the company.
Cns Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cns Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Cns Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cns Pharmaceuticals competition to find correlations between indicators driving Cns Pharmaceuticals's intrinsic value. More Info.Cns Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Cns Pharmaceuticals' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Cns Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Cns Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cns Pharmaceuticals' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cns Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Cns Pharmaceuticals by comparing valuation metrics of similar companies.Cns Pharmaceuticals is currently under evaluation in shares outstanding category among its peers.
Cns Fundamentals
| Return On Equity | -10.19 | ||||
| Return On Asset | -2.24 | ||||
| Current Valuation | (250.49 K) | ||||
| Shares Outstanding | 40.75 M | ||||
| Shares Owned By Insiders | 1.20 % | ||||
| Shares Owned By Institutions | 0.70 % | ||||
| Number Of Shares Shorted | 683.26 K | ||||
| Price To Earning | (13.70) X | ||||
| Price To Book | 2.00 X | ||||
| EBITDA | (18.86 M) | ||||
| Net Income | (18.85 M) | ||||
| Cash And Equivalents | 8.96 M | ||||
| Cash Per Share | 0.22 X | ||||
| Total Debt | 300.81 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 12.34 X | ||||
| Book Value Per Share | (2.98) X | ||||
| Cash Flow From Operations | (14.14 M) | ||||
| Short Ratio | 0.04 X | ||||
| Earnings Per Share | (352.97) X | ||||
| Target Price | 0.5 | ||||
| Beta | 1.05 | ||||
| Market Capitalization | 5.28 M | ||||
| Total Asset | 1.7 M | ||||
| Retained Earnings | (69.57 M) | ||||
| Working Capital | (4.54 M) | ||||
| Current Asset | 6.61 M | ||||
| Current Liabilities | 488.66 K | ||||
| Net Asset | 1.7 M |
About Cns Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cns Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cns Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cns Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | -5.2 M | -5 M | |
| Cost Of Revenue | 4.1 K | 3.9 K |
Pair Trading with Cns Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cns Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cns Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Cns Stock
| 0.67 | VALN | Valneva SE ADR | PairCorr |
| 0.76 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.64 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.62 | LLY | Eli Lilly Sell-off Trend | PairCorr |
Moving against Cns Stock
| 0.7 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.65 | GILD | Gilead Sciences | PairCorr |
| 0.54 | LPCN | Lipocine | PairCorr |
| 0.54 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.45 | OPT | Opthea | PairCorr |
The ability to find closely correlated positions to Cns Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cns Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cns Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cns Pharmaceuticals to buy it.
The correlation of Cns Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cns Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cns Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cns Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Cns Stock Analysis
When running Cns Pharmaceuticals' price analysis, check to measure Cns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cns Pharmaceuticals is operating at the current time. Most of Cns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cns Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.